Pharming shares drop on negative opinion for Rhucin

Thursday 20 March 2008

Share prices of the Pharming Group NV fell 25.6% after a committee of the European Medicines Agency (EMEA) reissued a negative opinion of its lead drug candidate, Rhucin, a treatment for hereditary angioedema (HAE).

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Netherlands